ClinicalTrials.gg
CompletedNCT04509622Updated May 5, 2022

A Study of Oral Venetoclax Tablet in Combination With Subcutaneous Low-Dose Cytarabine (LDAC) Injection to Assess Adverse Events in Adult Japanese Participants With Acute Myeloid Leukemia (AML)

A Phase 3 interventional study of Venetoclax and Cytarabine in Acute Myeloid Leukemia (AML), sponsored by AbbVie. Completed at 16 sites in Japan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-05-05.

Sponsored by AbbVie · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
14
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 202 studies testing venetoclax in Leukemia, Myeloid, Acute — 116 open to participants now, 144 under way, 21 of them phase 3. venetoclax · Leukemia, Myeloid, Acute.

Enrollment
184th of 202
14 · median 57
Started
2020
with 15 others
Phase 3
16 of 202
7 open now
Registered
51st of 202
by date
Lead sponsor
15 of 202
AbbVie

Among the 202 studies testing venetoclax in Leukemia, Myeloid, Acute, this one is the 184th largest by enrollment, is one of 16 that started in 2020, is one of 16 in phase 3, and was the 51st registered.

Leukemia, Myeloid, Acute

3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 817 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

116 of the 202 studies testing venetoclax in Leukemia, Myeloid, Acute are open now, in 12 countries. Recruiting first, the newest first:

111 more — sign in →

By country, each count listing its studies:

All 116 open studies →

About venetoclax

venetoclax: first FDA approval 2016 (VENCLEXTA), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 625 Leukemia, Myeloid, Acute studies recruiting now, 363 (58%) set no upper age limit and 222 (36%) stop at 75 or younger; 145 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 202 studies testing venetoclax in Leukemia, Myeloid, Acute, or all of them as a file.
02

Study summary

Acute Myeloid Leukemia (AML) is a cancer of the white blood cells which perform many functions, including fighting bacterial infections and defending the body against parasites. This study will evaluate how safe venetoclax is and assess the adverse events in adult participants with AML.

Venetoclax in combination with low-dose cytarabine (LDAC) is an approved therapy in the United States for patients with newly diagnosed acute myeloid leukemia (AML) aged > 18 years with a medical condition that prevents the use of intensive chemotherapy. This study provides access to venetoclax in combination with LDAC to participants over 18 years who are ineligible for intensive induction therapy. Around 38 adult participants with diagnosis of AML will be enrolled in approximately 15 sites across Japan.

Participants will receive oral venetoclax tablets once daily on days 1-28 in combination with subcutaneous low-dose cytarabine (LDAC) injections once daily on days 1-10 of the 28-day treatment cycles.

Participants will attend regular visits during the study at a hospital to evaluate safety by medical assessments and blood tests.

03

Conditions studied

  • Acute Myeloid Leukemia (AML)

Keywords

  • Acute Myeloid Leukemia (AML)
  • Cancer
  • Venetoclax, Venclexta
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Confirmed diagnosis of AML, previously untreated, ineligible for intensive induction regimen due to age or co-morbidities.
  • Participants who are >= 75 years of age or who are >= 18 to 74 years of age with at least one of the following co-morbidities:

    • (ECOG) performance status of 2 or 3.
    • Cardiac history of congestive heart failure requiring treatment or \<= 50% or chronic stable angina.
    • Diffusion capacity of lung for carbon monoxide (DLCO) \<= 65% or forced expiratory volume during the first second () \<= 65%.
    • Adequate renal and hepatic criteria as described in the protocol.
    • Other co-morbidities that the physician judges to be incompatible with intensive chemotherapy must be reviewed and approved by the AbbVie Therapeutic Area Medical Director (TA MD) before study enrollment.

Exclusion criteria

Exclusion Criteria:

  • History of prior treatment for AML with the exception of hydroxyurea, allowed through the first cycle of study treatment.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
14 participants (actual)

Study arms

  • Experimental
    Venetoclax + Low-Dose Cytarabine (LDAC)

    Participants will receive venetoclax once daily (QD) on days 1 through 28 plus LDAC QD on days 1 through 10 during the 28-day treatment cycles.

    Drug: Venetoclax · Drug: Cytarabine

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants with Adverse Events (AEs)

    An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study. A serious adverse event (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent any of the outcomes listed above.

    Time frame: Up to approximately 9 months after the first participant receives first dose of study drug

07

Study locations

16 sites
  • NHO Nagoya Medical Center /ID# 223671
    Nagoya-shi, Aichi 460-0001, Japan
  • Aichi Cancer Center Hospital /ID# 223134
    Nagoya-shi, Aichi 464-8681, Japan
  • University of Fukui Hospital /ID# 223133
    Yoshida-gun, Fukui 910-1193, Japan
  • Kyushu University Hospital /ID# 223136
    Fukuoka-shi, Fukuoka 812-8582, Japan
  • Gunmaken Saiseikai Maebashi Hospital /ID# 223301
    Maebashi-shi, Gunma 371-0821, Japan
  • National Hospital Organization Mito Medical Center /ID# 223392
    Higashi Ibaraki-gun, Ibaraki 311-3193, Japan
  • Hitachi General Hospital /ID# 223084
    Hitachi-shi, Ibaraki 317-0077, Japan
  • University Hospital Kyoto Prefectural University of Medicine /ID# 223135
    Kyoto-shi, Kyoto 602-8566, Japan
  • Tohoku University Hospital /ID# 223169
    Sendai-shi, Miyagi 9808574, Japan
  • Okayama University Hospital /ID# 222990
    Okayama-shi, Okayama 700-8558, Japan
  • Osaka City University Hospital /ID# 224269
    Osaka-shi, Osaka 545-8586, Japan
  • Saitama Medical University International Medical Center /ID# 223575
    Hidaka-shi, Saitama 350-1298, Japan
  • Juntendo University Hospital /ID# 223086
    Bunkyo-ku, Tokyo 113-8431, Japan
  • The Jikei University Daisan Hospital /ID# 223418
    Komae-shi, Tokyo 201-8601, Japan
  • NTT Medical Center Tokyo /ID# 223574
    Shinagawa-ku, Tokyo 141-8625, Japan
  • Yamagata University Hospital /ID# 223032
    Yamagata-shi, Yamagata 990-9585, Japan
08

References and documents

Individual participant data

Plan to share: Yes — AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data requests can be submitted at any time and the data will be accessible for 12 months, with possible extensions considered.

Access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). For more information on the process, or to submit a request, visit the following link.

Data sharing details ↗ · www.abbvie.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2020 to primary completion in Apr 2021, 6 months.

Of 43 industry-sponsored phase 3 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 62. This study's 6 months is below that.

Counting every sponsor, half of 121 studies reached it within 74 months; a quarter within 39 and three quarters within 99.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 10, 2020
First posted
Aug 12, 2020
StartActual
Oct 5, 2020
Primary completionActual
Apr 15, 2021
CompletionActual
Apr 15, 2021
Last update
May 5, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 5, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04509622
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Aug 12, 2020
Start date
Oct 5, 2020
Primary completion
Apr 15, 2021
Completion
Apr 15, 2021
Last update
May 5, 2022

Study contacts

ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Venetoclax · Cytarabine

Start the discussion